PressOctober 31, 2022 Silo Wellness to Testify on Oregon Psilocybin Therapy Land Use Restrictions at Jackson County Planning Commission’s Thursday Hearing; Other Corporate Updates
PressOctober 31, 2022 Soft Reboot Wellness’ Ketamine Depression Treatment Now Available for Los Altos
PressOctober 30, 2022 Clairvoyant’s Phase 2 Psilocybin Therapy Trial for Alcohol Use Disorder Obtains Regulatory Approval and Initiates 1st Clinical Site in Finland
PressOctober 30, 2022 Love Pharma – Johns Hopkins University Psilocybin Trial Advances Toward Launch in 2022
PressOctober 30, 2022 Mindset Pharma Announces Poster Presentations at Two Upcoming Scientific Conferences
PressOctober 30, 2022 Numinus Launches Psychedelic-Assisted Therapy for Chronic and Serious Medical Illness
PressOctober 29, 2022 COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022
PressOctober 27, 2022 Seelos Therapeutics to Sponsor and Participate in Wonderland, the World’s Leading Psychedelic Event
PressOctober 27, 2022 Delic Labs President and CSO Dr. Markus Roggen to Discuss the Importance of R&D for Business Growth at MJBizCon
BlogOctober 26, 2022 Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference
PressOctober 25, 2022 Silo Pharma – Distinctive with Ground-Breaking Research, Commitment to Developing Innovative Solutions
PressOctober 25, 2022 IntelGenx Receives FDA GDUFA Date for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film
